Showing results (91-100 of 116) with videos related to

Sort By:
Pageof 12
Annals of the Rheumatic Diseases|December 5, 2014
Discontinuation of tumour necrosis factor inhibitors in patients with rheumatoid arthritis in low-disease activity: persistent benefits. Data from the Corrona registryArthur Kavanaugh, Susan J Lee, Jeffrey R Curtis, et al.
Arthritis Research & Therapy|January 14, 2018
One-year risk of serious infection in patients treated with certolizumab pegol as compared with other TNF inhibitors in a real-world setting: data from a national U.S. rheumatoid arthritis registryLeslie R Harrold, Heather J Litman, Katherine C Saunders, et al.
The Journal of Rheumatology|May 3, 2020
Evaluation of Changes in Skin and Joint Outcomes and Associated Treatment Changes in Psoriatic Arthritis (PsA): Experience From the Corrona PsA/SpA RegistryPhilip J Mease, Carol J Etzel, William J Huster, et al.
RMD Open|June 28, 2019
Understanding the association between skin involvement and joint activity in patients with psoriatic arthritis: experience from the Corrona RegistryPhilip J Mease, Carol J Etzel, William J Huster, et al.
Arthritis Care & Research|May 26, 2017
Cluster-Randomized Trial of a Behavioral Intervention to Incorporate a Treat-to-Target Approach to Care of US Patients With Rheumatoid ArthritisLeslie R Harrold, George W Reed, Ani John, et al.
Arthritis Research & Therapy|April 28, 2016
Identifying factors associated with concordance with the American College of Rheumatology rheumatoid arthritis treatment recommendationsLeslie R Harrold, George W Reed, Joel M Kremer, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|March 5, 2014
A comparison of the malignancy incidence among patients with psoriatic arthritis and patients with rheumatoid arthritis in a large US cohortRachael L Gross, Julie S Schwartzman-Morris, Michael Krathen, et al.
Journal of Autoimmunity|June 26, 2017
Autoreactivity to malondialdehyde-modifications in rheumatoid arthritis is linked to disease activity and synovial pathogenesisCaroline Grönwall, Khaled Amara, Uta Hardt, et al.
Advances in Therapy|October 9, 2020
Real-World Evidence to Contextualize Clinical Trial Results and Inform Regulatory Decisions: Tofacitinib Modified-Release Once-Daily vs Immediate-Release Twice-Daily for Rheumatoid ArthritisStanley B Cohen, Jeffrey D Greenberg, James Harnett, et al.
Seminars in Arthritis and Rheumatism|August 3, 2010
A comparison of patient characteristics and outcomes in selected European and U.S. rheumatoid arthritis registriesJeffrey R Curtis, Archana Jain, Johan Askling, et al.
Pageof 12